Recent preclinical studies have shown that inhibiting GSH or Thioredoxin (Trx) antioxidant systems, which are downstream of Nrf2 signalling, can sensitise various tumour cell types to cancer therapy. This evidence concerns the gene NFE2L2 and neoplasm.